Avidity Biosciences To Present Phase 1/2 Data On Delpacibart Zotadirsen For Duchenne Muscular Dystrophy At 2025 World Muscle Society Congress

Author: Benzinga Newsdesk | October 06, 2025 09:06am

Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that it will deliver late-breaking oral and poster presentations at the 30th Annual International Congress of the World Muscle Society (WMS), to be held October 7-11, 2025, in Vienna, Austria.

The data to be presented at WMS will reinforce and build on the positive data announced by Avidity in September 2025 which showed reversal of disease progression and unprecedented improvement compared to baseline and natural history across multiple functional measures for participants living with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) treated continuously with delpacibart zotadirsen (del-zota) for one year in the Phase 1/2 EXPLORE44® and Phase 2 EXPLORE44-OLE™ trials. Del-zota is investigational, and it is not approved by the FDA. Its safety and efficacy have not been established.

30th Annual World Muscle Society Congress Presentations

• Delpacibart zotadirsen (del-zota) showed trends toward improvement in functional and patient-reported outcomes in individuals with DMD amenable to exon 44 skipping
  • Oral presentation: Kevin M. Flanigan, M.D., Nationwide Children's Hospital, to present on October 11, 2025, from 12:33 - 12:45 p.m. CET
• Delpacibart Zotadirsen (Del-zota) Increased Dystrophin and Improved Muscle Integrity Markers Regardless of Ambulatory Status in Individuals with DMD44
  • Poster presentation (674P): Aravindhan Veerapandiyan, M.D., Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, to present on October 8, 2025, from 2:30 - 3:30 p.m. CET

The presentation and poster will be available on the publications page of Avidity's website at https://www.aviditybiosciences.com.

Posted In: RNA